OCS - Oculis Holding AG Ordinary shares
Oculis Holding AG Ordinary shares Logo

OCS - Oculis Holding AG Ordinary shares

https://oculis.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors
GlobeNewswire • 3 weeks ago • score: 0.26
ZUG, Switzerland, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Oculis Holding AG ( Nasdaq: OCS / XICE: OCS ) ( "Oculis" ) , a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the appointments ...
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company is headquartered in Zug, Switzerland.

52W High
$23.08
52W Low
$11.56
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.11
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-3.47
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
1179.61
P/B (<3 favorable)
5.06
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
6.31%
Institutions (25–75% balanced)
31.17%
Shares Outstanding
52,336,000
Float
41,277,700
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
764,000
Gross Profit (TTM)
-53,678,000
EPS (TTM)
-2.89
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-79.57%
ROE (TTM) (>15% strong)
-0.84%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.07
Momentum
Bearish momentum
Value
-0.2030
Previous
-0.2516
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025